LGD-4033 (Ligandrol)
Synthetic peptide studied in animal and cell models for lean mass accretion and tissue-selective androgen activity
Last updated: March 1, 2026
- Compound
- LGD-4033 (Ligandrol)
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in animal and cell models for lean mass accretion, tissue-selective androgen activity, bone mineral density support.
- Mechanism
- Lean Mass Accretion and Composition Shift
- Research Status
- Phase II
- Routes Studied
- Oral administration
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About LGD-4033 (Ligandrol)?
- What is LGD-4033 (Ligandrol)?
- LGD-4033 (Ligandrol) is a synthetic peptide studied in animal and cell models for lean mass accretion and tissue-selective androgen activity.
- Is LGD-4033 (Ligandrol) clinically proven?
- No. Human evidence remains limited and does not establish LGD-4033 (Ligandrol) as clinically proven.
- What has LGD-4033 (Ligandrol) been studied for?
- LGD-4033 (Ligandrol) has been studied in preclinical models of lean mass accretion, tissue-selective androgen activity, bone mineral density support. These findings have not been confirmed in large-scale human trials.
- Is LGD-4033 (Ligandrol) approved?
- No. LGD-4033 (Ligandrol) is not an approved drug and remains a research compound.
What Is LGD-4033 (Ligandrol)?
LGD-4033, also known as Ligandrol or VK5211, is a non-steroidal selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals and subsequently licensed to Viking Therapeutics for clinical development. With the molecular formula C14H12F6N2O and a molecular weight of 338.25 g/mol, LGD-4033 is a small synthetic molecule that binds to androgen receptors with high affinity and selectivity. It is classified as a SARM, not a peptide, anabolic steroid, or prohormone,...
Evidence Summary
LGD-4033 (Ligandrol) is a research compound with promising biological signals but limited human validation. Most claims exceed current clinical evidence.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Lean Mass Accretion | Limited |
| Tissue-Selective Androgen Activity | Limited |
| Bone Mineral Density Support | Limited |
| Oral Bioavailability and Convenience | Limited |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
LGD-4033 (Ligandrol) is best understood as a compound with emerging clinical evidence that has not yet reached definitive conclusions. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for LGD-4033 (Ligandrol) is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has LGD-4033 (Ligandrol) Been Studied For?
Research areas where LGD-4033 (Ligandrol) has been investigated in published studies
-
Lean Mass Accretion LGD-4033 (Ligandrol) has been studied in animal models of lean mass accretion. These findings have not been confirmed in controlled human trials.
-
Tissue-Selective Androgen Activity LGD-4033 (Ligandrol) has been studied in animal models of tissue-selective androgen activity. These findings have not been confirmed in controlled human trials.
-
Bone Mineral Density Support LGD-4033 (Ligandrol) has been studied in animal models of bone mineral density support. These findings have not been confirmed in controlled human trials.
-
Oral Bioavailability and Convenience LGD-4033 (Ligandrol) has been studied in animal models of oral bioavailability and convenience. These findings have not been confirmed in controlled human trials.
How Does LGD-4033 (Ligandrol) Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 Selective Androgen Receptor Binding
- 02 Tissue-Specific Co-Regulator Recruitment
- 03 Downstream biological effect
- 04 Osteoblast Stimulation in Bone
Not sure if LGD-4033 (Ligandrol) is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about LGD-4033 (Ligandrol).
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate LGD-4033 (Ligandrol)
How Is LGD-4033 (Ligandrol) Administered?
LGD-4033 (Ligandrol) is available via Oral administration. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of LGD-4033 (Ligandrol)?
What Conditions Has LGD-4033 (Ligandrol) Been Linked To?
Have Questions About LGD-4033 (Ligandrol)?
Yes. LGD-4033 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category S1.2 (Other Anabolic Agents). It is also banned by most professional and amateur athletic organizations.
Published studies on LGD-4033 (Ligandrol) can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
LGD-4033 (Ligandrol) is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
Ready to discuss LGD-4033 (Ligandrol) with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026